Real-World Breast Cancer Studies Report Higher Response Rates Than Randomized Trials

When patients with hormone receptor-positive, HER2-negative advanced breast cancer receive CDK4/6 inhibitors, the outcomes reported in real-world studies differ measurably from those reported in randomized clinical trials. That is the central finding of a meta-epidemiological analysis published in BMC Cancer on 24 October 2026, which systematically compared single-arm outcomes across both types of evidence for the same drug class. After statistical adjustment, the model-based objective response rate was higher in real-world cohorts than in randomized trial arms, while symptom-based adverse events were consistently lower in routine-practice data.

The analysis, registered prospectively as PROSPERO CRD420261397529, searched PubMed, Embase, Cochrane CENTRAL, and Web of Science through December 2025. The team included phase 2 and phase 3 randomized trials as well as real-world cohort, registry, or postmarketing studies of CDK4/6 inhibitors combined with endocrine therapy, restricted to first- or second-line treatment of hormone receptor-positive, HER2-negative advanced or metastatic breast cancer. In total, 86 studies met the criteria: 31 randomized trials covering 40 treatment arms and 7,464 patients, and 55 real-world studies covering 101 cohorts and 30,858 patients.

The populations were not identical. Real-world cohorts enrolled older patients on average, and they contained a greater proportion of patients treated in the first-line setting and a greater proportion treated with palbociclib. To account for these imbalances, the researchers pooled arm-level proportions separately using logit-transformed random-effects models and then assessed differences between the two sources of evidence using aggregate-level mixed-effects meta-regression, adjusting at the study level rather than simply comparing raw pooled estimates.

After adjustment, the model-based objective response rate was 51.8 percent in real-world cohorts compared with 36.6 percent in randomized trial arms, a difference that remained statistically significant (P = .031). The authors point to how endpoints are defined, how denominators are constructed, and how outcomes are ascertained and reported as factors that can vary between a prospective trial protocol and a retrospective cohort, registry, or postmarketing study, shaping the numbers that each setting produces.

Safety outcomes told a more nuanced story. Adverse events measured through laboratory testing did not differ significantly between the two settings. In contrast, adverse events based on patient symptoms were consistently lower in real-world cohorts. Discontinuation due to adverse events was statistically similar across settings, at 10.6 percent in real-world cohorts versus 8.6 percent in trial arms (P = .523). However, dose reduction related to adverse events was significantly higher in real-world cohorts, at 50.8 percent versus 33.4 percent (P = .016).

The authors conclude that reported single-arm outcomes differed between randomized trials and real-world studies, with the largest differences observed for response and symptom-based adverse-event outcomes. They caution that these estimates should be interpreted according to endpoint definition, denominator construction, ascertainment, and reporting. For oncologists and regulators, the practical implication is that real-world evidence and randomized trial evidence for CDK4/6 inhibitors should not be read as interchangeable benchmarks: a response rate of roughly 52 percent drawn from real-world cohorts and one of roughly 37 percent drawn from trial arms reflect different measurement contexts as much as different patient populations, a caution that applies broadly as real-world evidence takes an increasing role alongside randomized trials in oncology.

Subject of Research: Comparison of reported outcomes for CDK4/6 inhibitors in advanced breast cancer between randomized trials and real-world studies

Article Title: Outcome-specific differences between randomized trials and real-world studies of CDK4/6 inhibitors in hormone receptor-positive, HER2-negative advanced breast cancer: a meta-epidemiological analysis

Article References: Sun, L., Yang, X., Zhou, D., Zhao, M., Ke, X., Zhu, L., Huang, J., & Tian, L. (2026). Outcome-specific differences between randomized trials and real-world studies of CDK4/6 inhibitors in hormone receptor-positive, HER2-negative advanced breast cancer: a meta-epidemiological analysis. BMC Cancer. https://doi.org/10.1186/s12885-026-17197-3

Image Credits: AI Generated

DOI: 10.1186/s12885-026-17197-3

Keywords: CDK4/6 inhibitors, advanced breast cancer, hormone receptor-positive, HER2-negative, real-world evidence, randomized trials, meta-epidemiology, objective response rate, adverse events, palbociclib, endocrine therapy, BMC Cancer